(Q34283336)

1 August 2017

title

Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level (English)

1 reference

1 August 2017

main subject

anti-retroviral agent

0 references

Robert S Hogg

6

0 references

David R Bangsberg

series ordinal

2

object named as

David R Bangsberg

1 reference

1 August 2017

4

Steven G Deeks

1 reference

1 August 2017

7

Julio S G Montaner

1 reference

1 August 2017

5

Benita Yip

1 reference

1 August 2017

3

P Richard Harrigan

1 reference

1 August 2017

Viviane D Lima

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Journal of Acquired Immune Deficiency Syndromes

1 August 2017

published in

1 reference

1 August 2017

volume

55

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

460-465

1 reference

The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Drug resistance mutations in HIV-1.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974791

Adherence to triple therapy and viral load response

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20838225

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/QAI.0B013E3181F2AC87

1 reference

1 August 2017

1 reference

1 August 2017

1 reference